Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Sotio Biotech Inc.
PMV Pharmaceuticals, Inc
NeoImmuneTech
Neonc Technologies, Inc.
ImmunityBio, Inc.
VM Oncology, LLC
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Blanco, Dr Antonio Calles MD
OncoC4, Inc.